Regeneron Pharmaceuticals is a biotechnology business based in the US. Regeneron Pharmaceuticals shares (REGN) are listed on the NASDAQ and all prices are listed in US Dollars.
Its last market close was $710.00 – an increase of 5.5% over the previous week. Regeneron Pharmaceuticals employs 14,165 staff and has a trailing 12-month revenue of around $13.8 billion.Our top picks for where to buy Regeneron Pharmaceuticals stock
How to buy Regeneron Pharmaceuticals stock
- Choose a stock trading platform. Compare investment platforms.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – REGN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Regeneron Pharmaceuticals, Inc. stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Note: The dollar amounts in the table below are in Canadian dollars.
Finder Score for stock trading platforms
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.
Regeneron Pharmaceuticals stock price (NASDAQ: REGN)
Use our graph to track the performance of REGN stocks over time.Regeneron Pharmaceuticals stocks at a glance
Latest market close | $710.00 |
---|---|
52-week range | $642.00 - $1,211.20 |
50-day moving average | $720.14 |
200-day moving average | $945.25 |
Wall St. target price | $939.37 |
PE ratio | 18.8333 |
Dividend yield | N/A |
Earnings per share (TTM) | $38.34 |
Is it a good time to buy Regeneron Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Regeneron Pharmaceuticals price performance over time
Historical closes compared with the close of $722.07 from 2025-02-06
1 week (2025-01-31) | 7.29% |
---|---|
1 month (2025-01-08) | -1.57% |
3 months (2024-11-08) | -12.84% |
6 months (2024-08-08) | -35.14% |
1 year (2024-02-08) | -23.71% |
---|---|
2 years (2023-02-08) | -3.68% |
3 years (2022-02-08) | 16.85% |
5 years (2020-02-07) | 89.09% |
Is Regeneron Pharmaceuticals stock undervalued or overvalued?
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's P/E ratio
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Regeneron Pharmaceuticals shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stock or simply that they're under-valued.
Regeneron Pharmaceuticals's PEG ratio
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.152. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 billion.
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Regeneron Pharmaceuticals financials
Revenue TTM | $13.8 billion |
---|---|
Operating margin TTM | 33.43% |
Gross profit TTM | $7 billion |
Return on assets TTM | 7.41% |
Return on equity TTM | 17.17% |
Profit margin | 33.61% |
Book value | $272.04 |
Market Capitalization | $78.9 billion |
TTM: trailing 12 months
Regeneron Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Regeneron Pharmaceuticals's total ESG risk score
Total ESG risk: 22.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 12/31/2018) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Regeneron Pharmaceuticals's environmental score
Environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's social score
Social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Regeneron Pharmaceuticals's governance score
Governance score: 5.88/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Regeneron Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.
Total ESG score | 22.33 |
---|---|
Total ESG percentile | 26.82 |
Environmental score | 1.51 |
Environmental score percentile | 2 |
Social score | 13.94 |
Social score percentile | 2 |
Governance score | 5.88 |
Governance score percentile | 2 |
Level of controversy | 2 |
Regeneron Pharmaceuticals stock dividends
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.
Regeneron Pharmaceuticals stock price volatility
Over the last 12 months, Regeneron Pharmaceuticals's stocks have ranged in value from as little as $642 up to $1211.2. A popular way to gauge a stock's volatility is its "beta."
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.142. This would suggest that Regeneron Pharmaceuticals's stocks are less volatile than average (for this exchange).
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc.
Frequently asked questions
What percentage of Regeneron Pharmaceuticals is owned by insiders or institutions?Currently 1.57% of Regeneron Pharmaceuticals stocks are held by insiders and 90.728% by institutions. How many people work for Regeneron Pharmaceuticals?
Latest data suggests 14,165 work at Regeneron Pharmaceuticals. When does the fiscal year end for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals's fiscal year ends in December. Where is Regeneron Pharmaceuticals based?
Regeneron Pharmaceuticals's address is: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 What is Regeneron Pharmaceuticals's ISIN number?
Regeneron Pharmaceuticals's international securities identification number is: US75886F1075 What is Regeneron Pharmaceuticals's CUSIP number?
Regeneron Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75886F107
More on investing

How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…
What are stocks?
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
Read more…More guides on Finder
-
Best renewable energy stocks
These are the best renewable energy stocks to buy now in Canada.
-
Best stocks to buy right now in Canada
Finder’s unique algorithm found the 20 best TSX stocks to buy right now.
-
5 Best ETFs in Canada for 2025
Looing for the best performing ETF in Canada? Explore the best Canadian ETFs on the TSX for dividend, REIT, bond investing and more.
-
4 Best US ETFs for 2025
Looing for the best US ETF? Explore the best US ETFs, including top US dividend and Nasdaq funds.
-
10 best stock trading platforms and apps in Canada for 2025
Whether you’re a new or experienced investor, these are the best stock trading platforms and apps in Canada.
-
How to buy US stocks in Canada
Buying US stocks in Canada is easier than you think. Find out how to buy US stocks in 4 simple steps.
-
How to invest in the S&P 500 in Canada
Find out how to invest in the S&P 500 in Canada—one of the world’s most popular stock indices—to diversify your portfolio.
-
BMO InvestorLine review
Check out the pros and cons of BMO’s self-directed trading platform in our InvestorLine review.
-
How to trade options in Canada
What is options trading and are options better than stocks? Learn how options trading in Canada works.
-
How to buy stocks in Canada
Want to know how to buy and sell stocks in Canada? Find out what you need to know in this simple, step-by-step guide.